作者
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Gurmit Singh, Jay JH Park, Jamie I Forrest, Ofir Harari, Castilho Vitor Quirino Dos Santos, Ana Paula Figueiredo Guimarães de Almeida, Adhemar Dias de Figueiredo Neto, Leonardo Cançado Monteiro Savassi, Aline Cruz Milagres, Mauro Martins Teixeira, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Edward J Mills, TOGETHER Investigators
发表日期
2021/4/1
期刊
JAMA Network Open
卷号
4
期号
4
页码范围
e216468-e216468
出版商
American Medical Association
简介
Importance
Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed.
Objective
To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting.
Design, Setting, and Participants
This randomized clinical trial was conducted in Brazil. Recently symptomatic adults diagnosed with respiratory symptoms from SARS-CoV-2 infection were enrolled between June 2 and September 30, 2020. The planned sample size was 1476 patients, with interim analyses planned after 500 patients were enrolled. The trial was stopped after the interim analysis for futility with a sample size of 685 patients. Statistical analysis was performed in December 2020.
Interventions
Patients were randomly assigned to hydroxychloroquine (800 mg …
学术搜索中的文章
G Reis, EASM Silva, DCM Silva, L Thabane, G Singh… - JAMA Network Open, 2021